Please assess the completion status of the following clinical trial:

Trial Title: Behavioral Effects of Kuvan in Children With Mild Phenylketonuria

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Willing and able to provide informed consent and/or assent.~* Willing and able to comply with study procedures.~* Between 6 and 18 years of age, inclusive.~* Intention of physician to prescribe Kuvan.~* Phenylalanine levels between 360μmol/L and 600μmol/L, inclusive, when untreated with dietary restrictions.~* Negative pregnancy test if of childbearing potential.~* Willing to use contraception if sexually active.~Exclusion Criteria:~* Treatment with Kuvan within the past 6 months.~* Pregnant, breastfeeding, or planning to become pregnant during study.~* Use of investigational product less than 30 days prior to or during study.~* Concurrent condition that could interfere with participation or safety.~* Any condition creating high risk of poor compliance with study.~* History of major medical disorder unrelated to phenylketonuria.~* Perceived to be unreliable or unavailable for study.~* Use of L-Dopa, methotrexate, or other drugs that inhibit folate metabolism.~* Known hypersensitivity to sapropterin or excipients.

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: 18 Years
- Healthy Volunteers: f

Study Arms:
- Phenylketonuria (Type: None): Individuals with mild phenylketonuria/hyperphenylalanemia who are beginning treatment with Kuvan.

Based on this trial design, predict the completion outcome and termination type (if applicable).